

Applicant : Tamar H. Michaeli
Serial No. : Unknown
Filed : February 27, 2002 (herewith)
Page 4

phosphodiesterase 1C.

11. The method of claim 10, wherein the inhibitor is an isobutylmethylxanthine derivative with substitutions at positions 2 (R1) and 8 (R2).

12. The method of claim 11, wherein R1 and R2 are independently a moiety selected from the group consisting of an alkyl (C₁ to C₃), a fluoroalkyl (F₁ to F₃), a chloroalkyl (Cl₁ to Cl₃), an aryl (C₅ to C₆), a fluoroaryl (F₁ to F₂), and a chloroaryl (Cl₁ to Cl₂).

13. The method of claim 10, wherein the inhibitor is selected from the group consisting of IBMX, zaprinast, 8-methoxymethyl-1-methyl-3-(2-methylpropyl)xanthine (8MM-IBMX), and combinations thereof.

14. The method of claim 13, wherein the inhibitor is zaprinast.

15. The method of claim 13, wherein the inhibitor is 8-methoxymethyl-1-methyl-3-(2-methylpropyl)xanthine (8MM-IBMX).

16. The method of claim 10, wherein the mammal is a human.

17. The method of claim 10, wherein the inhibitor is administered in an amount effective to regulate blood sugar levels in the mammal.

18. The method of claim 10, wherein the inhibitor is administered orally.

Applicant : Tamar H. Michaeli
Serial No. : Unknown
Filed : February 27, 2002 (herewith)
Page 5

19. The method of claim 10, wherein the inhibitor is administered in combination with an anti-diabetic agent selected from the group consisting of insulin, a sulfonylurea, and a biguanide.

Remarks

Applicant has entered specification amendments that provide priority information or that were previously entered in the parent case. Applicant has also amended the claims to be directed to methods of increasing glucose dependent insulin secretion in a pancreatic β -cell in mammals. Applicant asserts that the new claims are fully supported in the specification as filed.

Support for claim 10 is found at least in the Experimental Details section, at pages 25-47.

Support for claim 11 is found at least at page 19, line 25 to page 20 line 4.

Support for claim 12 is found at least at page 11, lines 10-18.

Support for claims 13-15 is found in the Experimental Details section, at pages 25-47.

Support for claim 16 is found at least at page 20, lines 11-27.

Support for claim 17 is found at least in the originally filed claims.

Support for claim 18 is found at least at page 21, line 22 to page 22, line 13.

Finally, support for claim 19 is found at least at page 24, line 17 to page 25, line

3.